Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris
Daix (France), February 10, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the French market authority (Autorité des Marchés Financiers, or AMF) approved a prospectus under number 20-034 on February 7, 2020 in the context of the admission to trading of new shares on the regulated market of Euronext in Paris. 3,778,338 new shares are issued by way of a capital increase without the exercise of preemptive subscription rights in favor of categories of persons with specific characteristics for an amount of €15 million for a subscription price of €3.97 each (including premium).
The prospectus includes:
– the universal registration document filed with the AMF on February 7, 2020 under no D.20-0038;
– the securities note; and
– the summary of the prospectus (included in the securities note).
These documents may be consulted on the Company’s website at www.inventivapharma.com, in the “Investors” section, and on the AMF’s website at www.amf-france.org. Printed copies of the universal registration document are also available to the public free of charge and upon request at the Company’s headquarters located 50 Rue de Dijon, 21121 Daix, France.Download PDF